Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
Basel, October 07 , 2026 – Novartis will present new data from its multiple sclerosis (MS) portfolio with 46 abstracts at MSToronto2026, the 10th Joint ACT